These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23823695)

  • 21. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
    Wang Y; Wu D; Sun A; Jin Z; Qiu H; Miao M; Tang X; Fu Z
    Int J Hematol; 2008 Mar; 87(2):167-171. PubMed ID: 18288566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
    Olavarria E; Siddique S; Griffiths MJ; Avery S; Byrne JL; Piper KP; Lennard AL; Pallan L; Arrazi JM; Perz JB; O'Shea D; Goldman JM; Apperley JF; Craddock CF
    Blood; 2007 Dec; 110(13):4614-7. PubMed ID: 17881635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
    Lee SJ; Kukreja M; Wang T; Giralt SA; Szer J; Arora M; Woolfrey AE; Cervantes F; Champlin RE; Gale RP; Halter J; Keating A; Marks DI; McCarthy PL; Olavarria E; Stadtmauer EA; Abecasis M; Gupta V; Khoury HJ; George B; Hale GA; Liesveld JL; Rizzieri DA; Antin JH; Bolwell BJ; Carabasi MH; Copelan E; Ilhan O; Litzow MR; Schouten HC; Zander AR; Horowitz MM; Maziarz RT
    Blood; 2008 Oct; 112(8):3500-7. PubMed ID: 18664621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Olavarria E; Ottmann OG; Deininger M; Clark RE; Bandini G; Byrne J; Lipton J; Vitek A; Michallet M; Siegert W; Ullmann A; Wassmann B; Niederwieser D; Fischer T;
    Leukemia; 2003 Sep; 17(9):1707-12. PubMed ID: 12970768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
    Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV
    Blood; 2010 Aug; 116(8):1329-35. PubMed ID: 20462961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XY; Han W; Zhang XH; Wang Y; Zhang YY; Qin YZ; Liu YR; Huang XJ
    J Hematol Oncol; 2012 Jun; 5():29. PubMed ID: 22682059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
    Angstreich GR; Smith BD; Jones RJ
    Curr Opin Oncol; 2004 Mar; 16(2):95-9. PubMed ID: 15075898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
    Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
    Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
    Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
    Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
    Medeiros BC; Chun K; Kamel-Reid S; Lipton J
    Am J Hematol; 2007 Aug; 82(8):758-60. PubMed ID: 17301975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Wassmann B; Pfeifer H; Stadler M; Bornhaüser M; Bug G; Scheuring UJ; Brück P; Stelljes M; Schwerdtfeger R; Basara N; Perz J; Bunjes D; Ledderose G; Mahlberg R; Binckebanck A; Gschaidmeier H; Hoelzer D; Ottmann OG
    Blood; 2005 Jul; 106(2):458-63. PubMed ID: 15817679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation.
    Shanavas M; Messner HA; Kamel-Reid S; Atenafu EG; Gupta V; Kuruvilla J; Kim DD; Uhm J; Lambie A; Ellis L; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):87-92. PubMed ID: 24252361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.
    Schmidt S; Liu Y; Hu ZH; Williams KM; Lazarus HM; Vij R; Kharfan-Dabaja MA; Ortí G; Wiernik PH; Weisdorf D; Kamble RT; Herzig R; Wirk B; Cerny J; Bacher U; Chaudhri NA; Nathan S; Farhadfar N; Aljurf M; Gergis U; Szer J; Seo S; Hsu JW; Olsson RF; Maharaj D; George B; Hildebrandt GC; Agrawal V; Nishihori T; Abdel-Azim H; Alyea E; Popat U; Sobecks R; Scott BL; Holter Chakrabarty J; Saber W
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1137-1143. PubMed ID: 32062061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
    Yujiri T; Sato Y; Tanizawa Y
    Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.